Biosimilars Market Role in Reducing Healthcare Costs and …
2024年12月9日 · The global biosimilars market is witnessing remarkable growth, driven by factors such as cost efficiency, increased demand for accessible healthcare solutions, and the expiration of patents for branded biologic drugs. With a market that was valued at approximately USD 20.4 billion in 2021, the biosimilars market is expected to expand significantly, reaching more than USD 85 billion by the end ...
Ottimo Pharma Emerges from Stealth with Backing from Medicxi …
2024年10月28日 · · David Epstein, formerly CEO of Seagen, joins as Chair & Chief Executive Officer · Mehdi Shahidi, previously SVP and Chief Medical Officer at Boehringer Ingelheim, joins as Head of Development & Chief Medical Officer · James Sabry, ex-Head of Pharma Partnering at Roche, joins the Board as Vice-Chair [28 October 2024]: [London, UK/ Boston, US]: Ottimo Pharma, a private biotech company ...
HUTCHMED Announces US$608 million Divestment of Non-Core …
5 天之前 · HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (“SHPL”) for approximately US$608 million (RMB4,478 million) in cash, to GP Health Service Capital Co., Ltd (“GP Health ...
Naobios and Sumagen successfully optimize HIV vaccine …
2024年10月29日 · Key milestone reached within expected initial timelines with successful set up of cell growth and production of HIV-1 vaccine candidate at bench scalePhase I/II trial to assess safety and efficacy expected to start after cGMP production end of 2025 Nantes, France October 29, 2024 – Naobios, a CDMO (Contract Developm...
Combination of Poolbeg and HOOKIPA Pharma Inc
5 天之前 · The boards of directors (each a "Board") of HOOKIPA Pharma Inc. ("HOOKIPA") and Poolbeg Pharma plc ("Poolbeg") are pleased to announce that they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg (the "Potential Combination") to create a strong clinical-stage biopharmaceutical company focused on developing and commercialising innovative medicines for ...
CPHI returns to the Messe Frankfurt in 2025 - PharmiWeb.com
2024年7月2日 · The Heart of Pharma will return to Europe’s leading pharma manufacturing region. Frankfurt, Monday, 1st July, 2024 - The world's largest pharmaceutical event, CPHI Europe, will return to Messe Frankfurt in 2025, scheduled for 28-30 October. The event will bring together the entire supply chain, from ingredients and finished dosages to machinery, bio, packaging, and more.
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated ...
Paris, October 25, 2024Q3 sales growth of 15.7% at CER and business EPS(1) of €2.86Dupixent sales up 23.8% to €3,476 million; full-year 2024 target of ~€13 billion confirmedPharma launches up 67.1% to €727 million, led by ALTUVIIIO, Nexviazyme and RezurockVaccines sales up 25.5%, boosted by phasi...
enVVeno Medical Submits the VenoValve PMA Application …
2024年11月19日 · Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium. Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20 th at 2:00 PM Eastern Time - Click Here to Access. IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company ...
Global Sialendoscopes Market Set for Significant Growth, …
2024年12月2日 · The global sialendoscopes market is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) of 5.6% from 2022 to 2032, according to recent industry analysis. In 2022, the market achieved a revenue of USD 169.2 million, and it is expected to surpass USD 307.9 million by 2032, signaling strong demand for advanced diagnostic and therapeutic tools for salivary gland ...
Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T …
2024年12月19日 · Collaboration with Kure.ai to develop ultrafast CAR-T manufacturing process for Hemogenyx Pharmaceuticals' AML Treatment. LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood malignancies, and Kure.ai ("Kure"), a leader in ultrafast CAR-T manufacturing technology, are pleased ...